I was exploring therapeutic activation of PPAR gamma in Type 2 diabetes, I wanted to know why partial agonists are used?

I understood that full PPAR agonists (like Thiazolidinediones) resulted in severe side effects and this is why the switch to exploring partial agonists was made. But doesn't the partial...

19 November 2021 2,983 6 View